As the world faced a public health emergency with skyrocketing COVID-19 infections starting in 2020, the diagnostics industry received more mainstream attention than ever before. News about the need for, and importance of, diagnostic solutions headlined news reports daily.
Diagnostics play a critical role in successfully navigating the infectious diseases landscape and managing infections that are even more common and more deadly, such as sepsis. GenMark Diagnostics (GenMark) recognized the need to raise awareness of its diagnostics solutions and engaged PCI to support the launch of its Respiratory Pathogen Panel 2 (RP2), a syndromic test that provides rapid results for infections with similar symptoms such as fever, cough and body aches, including COVID-19, flu, bronchitis and the common cold.